Site of Drug Action: Dose Responses

Beschreibung

Introductory Pharmacology Mindmap am Site of Drug Action: Dose Responses, erstellt von Daniel Elandix G am 01/08/2013.
Daniel Elandix G
Mindmap von Daniel Elandix G, aktualisiert more than 1 year ago
Daniel Elandix G
Erstellt von Daniel Elandix G vor mehr als 11 Jahre
79
0

Zusammenfassung der Ressource

Site of Drug Action: Dose Responses

Anmerkungen:

  • Pharmacology is the study of the action of drugs on living tissue. Drug is an agent that interacts with specific target molecule in the body and produce a physiological effect
  1. Pharmacodynamics

    Anmerkungen:

    • Mechanism by which drugs exert their effect on the body to generate a therapeutic action.
    1. Types of Drugs

      Anmerkungen:

      • Activity at high concentrations (non-potent). Little Structural specificity. Physical changes Drug acting at low concentrations (potent). Structural specificity, chemical interaction
      1. Receptors

        Anmerkungen:

        • Site where ligand can attach. Ligands can be neurotransmitter, hormones or other factors. Activation produces a response. Receptors can be determined by Affinity or selectivity
        1. Types

          Anmerkungen:

          • Most commonly G-protein coupled receptors, e.g acetylcholine, opoids, noradrenaline Ligand-Gated ion channel Kinase-lined receptors (Cytokines/growth factors) Nuclear Receptors (i.e vitamin D receptors)
          1. Subtypes

            Anmerkungen:

            • Cholinergic: Either muscarinic or nicotinic Include B2, B1 or A1 (lungs, heart, blood vessels) Hence it is important to develop drugs that are specific to minimize side effects. As Receptor occurs in multiple tissues. Drugs could also be non specific, acting on more than receptors. Hence the need of trials on healthy human in the 1st phase.
      2. Drug Action

        Anmerkungen:

        • Many categories include: Agonists Antagonists Partial Agonist Inverse Agonist Allosteric Modulators
        1. Agonist

          Anmerkungen:

          • Mimics endogenous ligands, bind to receptor and cause a secondary effect.
          1. Receptor interactions

            Anmerkungen:

            • Assume that: Effect of drug is proportional to the fraction of receptors occupied Maximal effect occurs when all receptors are occupied
            1. Measurement of Receptor Binding

              Anmerkungen:

              • Total receptor bound - nonspecific binding = Specific binding. 2 factors: Binding of drug to receptor: Affinity Response to binding: Efficacy (Capacity to produce an effect)
              1. ED50

                Anmerkungen:

                • Effective Dose 50% (amount taken by human/animal) Effective concentration 50% ( Concentration needed for a given cell/tissue to work) Look at lecture notes for more details. Basically this is just a measurement on how to do a dose-response measurement.
            2. Antagonist

              Anmerkungen:

              • Prevents action of the agonist. When an antagonist act on the receptors, nothing happens, hence you need to have a agonist for the effect to be fully noticeable.
              1. Competitive Antagonism

                Anmerkungen:

                • Most common form of antagonist. Agonist and antagonist compete for the same receptor site. Maximal effect is unchanged as antagonism is surmountable. Maximum takes longer time to reach hence the graph has a parallel shift to the right
                1. Physiological Antagonism

                  Anmerkungen:

                  • When 2 agonist had an effect of 2 opposite effects. I.e alcohol with caffeine
                  1. Non-competitive Antagonism

                    Anmerkungen:

                    • Antagonist that binds irreversibly to the receptor. Change the receptor binding site so that the agonist can no longer bind. Maximal effect is no longer produced.  Graph, lowered plus lowered slope.
                    1. Spare Receptors

                      Anmerkungen:

                      • Spare receptors are important as it allow maximum response to be reached. This means that the ED50 may not be equal to KD as there are existence of spare receptors.
                    2. Inverse Agonist

                      Anmerkungen:

                      • Opposite effect of agonist, cause an effect to be going the other way. Increase presence of inverse receptors. Effects still being researched.
                    3. Partial Agonist

                      Anmerkungen:

                      • Partial agonist is an agonist, however they have low efficacy and they never achieve maximum effect. They may act as an against a full agonist as an antagonist.
                      1. Allosteric Modulators

                        Anmerkungen:

                        • Weird interactions. Bind to the separate sites other than the agonists. Either they can increase or decrease modulation.
                      2. Measurement

                        Anmerkungen:

                        • In quantitative response: Gradual changes, i.e blood pressure Quantal response: All or nothing.
                        1. Therapeutic Ratio

                          Anmerkungen:

                          • LD50/ED50 Toxic ratio: TD50/ED50
                        2. Receptor Numbers

                          Anmerkungen:

                          • It is ever changing, receptors are continuously removed and replaced.  I.e if too much agonist, down regulation, increased tolerance or desensitisation. If too much antagonist, up regulation. sensitization may occur.
                          1. Tolerance

                            Anmerkungen:

                            • Tolerance: Same dose, administrated repeatedly, less effect Tachyphylaxis: Tolerance which develops too fast Desensitization: Less effect is produced the longer agonist is in contact with the receptor. Change in receptors, down regulation and the depletion of mediators or increased metabolic breakdown increases sensitization.
                          Zusammenfassung anzeigen Zusammenfassung ausblenden

                          ähnlicher Inhalt

                          Autonomic Pharmacology
                          Daniel Elandix G
                          Drugs of Addiction
                          Daniel Elandix G
                          Pharmacology of Autocoids
                          Daniel Elandix G
                          Drug Metabolism/Excretion
                          Daniel Elandix G
                          Regulation of Neurotransmitter
                          Daniel Elandix G
                          H. Pylori and Peptic Ulcer Disease
                          Daniel Elandix G
                          Adrenergic Mechanisms
                          Daniel Elandix G
                          Agonist and Antagonists
                          Daniel Elandix G
                          Complementary and Alternative Medicine
                          Daniel Elandix G
                          Neutraceuticals
                          Daniel Elandix G